Genetic Technologies Ltd. ADR (GENE) News

Genetic Technologies Ltd. ADR (GENE): $1.27

0.01 (+0.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GENE News Items

GENE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GENE News From Around the Web

Below are the latest news stories about Genetic Technologies Ltd that investors may wish to consider to help them evaluate GENE as an investment opportunity.

US Patent Office Grants Patent for COVID-19 Risk Test

MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection. The granted US patent covers the proprietary technology incorporated into GENE’s geneType COVID-19 Risk Test, which provides a probability

Yahoo | February 23, 2022

GeneType Multi-Test Receives Regulatory Approval for Commercial Release in USA and Australia

MELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that on February 17, 2022 the Company’s laboratory in Fitzroy, Melbourne has received simultaneous NATA accreditation and US Centers for Medicare and Medicaid Services (CMS) CLIA-certification enabling the commercial launch of the GeneType Multi-Test in Australia a

Yahoo | February 22, 2022

Genetic Technologies Reports Q2 FY22 Cash Flow Results

Q2 momentum sets the stage for a strong FY22MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a diversified Genomics and AI driven preventative health business, provides its results for the quarter ended December 31, 2021. Highlights: Solid cash balance of A$13.5 million and increased customer receipts of A$1.8 million further extending runway for growth‘One company two brands’ approach leverages EasyDNA

Yahoo | January 19, 2022

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a global leader in genomics-based tests in health, wellness and serious disease provides the following business update:

Cash Receipts (A$'000) Cash Receipts (A$'000) Forecast 2QFY221 cash receipts +112% versus the prior quarter (1QFY22) to A$1.8 million following the completed integration of EasyDNA in the quarterMulti-Test technical validation complete and submitted to NATA2 and CMS3 for final regulatory approval ahead of the commercial releaseUS patent application for novel geneType COVID-19 Risk Test has been accepted and cross validation study completed in independent cohort confirming test performance and ut

Yahoo | December 21, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | December 10, 2021

GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium

MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium. New geneType Breast Cancer Test showed improved discrimination and calibration over traditional clinical modelsStudy included over

Yahoo | December 10, 2021

Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTO

MELBOURNE, Australia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s US patent application for its novel geneType COVID-19 Risk Test has been accepted: New partnership agreement signed with IBX and 1health expands patient access in USPatent accepted by United States Patent and Trademark Office (“USPTO”) for the geneType COVID-19

Yahoo | December 9, 2021

Genetic Technologies Reports Q1 FY22 Results

Genetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts over prior quarterMELBOURNE, Australia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease provides its results for its first quarter of fiscal year 2022, ended September 30, 2021. Highlights Cash receipts of A$850k, a material increase on th

Yahoo | October 25, 2021

GENE Delivers Material 12-Fold Increase in Revenue in the Quarter Ended September 2021

Commercialisation plans gather momentumMELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, announces a 12-fold increase in revenue generated during the September 2021 quarter to A$850k1. Highlights: Delivering a material 12-fold increase in customer receipts to A$850k, versus June 2021 quarterRevenue primarily derived from license and resa

Yahoo | October 4, 2021

Genetic Technologies Limited Interview to Air on Bloomberg TV (U.S.) on the RedChip Money Report®

MELBOURNE, Australia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, today announced that an interview with CEO Simon Morriss, discussing the advancements on their commercialization plans, the recent acquisition of EasyDNA and the associated near term material revenue increase, will air on The RedChip Money Report® on Bloomberg TV (U.S.), Saturday, October

Yahoo | September 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5145 seconds.